Barclays Maintains Overweight on Globus Medical, Raises Price Target to $85
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Matt Miksic has maintained an Overweight rating on Globus Medical (NYSE:GMED) and increased the price target from $83 to $85, indicating a positive outlook on the company's stock.
May 09, 2024 | 3:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays has maintained an Overweight rating on Globus Medical and raised the price target from $83 to $85.
The increase in price target by Barclays, accompanied by an Overweight rating, suggests a strong confidence in Globus Medical's future performance. This endorsement from a reputable analyst is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100